Bhagirathbhai Dholaria

October 4, 2024

‘Off-the-shelf’ CAR-T therapy shows promise for relapsed/refractory multiple myeloma 

The therapy, P-BCMA-ALL01, demonstrated a 91% overall response rate for the 23 patients participating in the phase 1 trial.

By Tom Wilemon